Rhinostics has launched its new device, VERIstic, which focuses on the collection of small volume blood and is designed for use in at-home and clinician-assisted collection processes.
It serves as a high-throughput replacement for the detection of proteins, antibodies and hormones, as well as other applications that use finger prick collection, such as testing for sexually transmitted infections (STIs), genetic testing, dried blood spot (DBS) cards and clinical trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The VERIstic collection device is claimed to be the first of its kind to combine new capillary blood collection with an integrated, automation-ready cap.
The design of the patent-pending three-sided capillary device combines tried-and-true wicking action for the collection of 50µL of blood with automated, walkaway processing that saves time and money.
The tube is then screwed into a matching transport tube to be sent to the laboratory.
The new device makes the collection of blood samples quick, simple and comfortable for patients and clinicians.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRhinostics president and CEO Cheri Walker said: “Finally, patients and clinicians can be assured of comfortable metered blood collection, where the clear capillary allows the collector to monitor collection and laboratories gain consistent blood collection combined with cost and time-saving efficiencies during processing through automated decapping and robotic sample processing.”
The company noted that VERIstic is suitable for various applications, including wound care, blood monitoring, clinical trials, other small volume body fluids, and many home- or clinic-based sample collection needs.
In May, Rhinostics and Nexus Medical Labs received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for a molecular SARS-CoV-2 test.
